Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL11182899 | 1.00 | TSHR (0.60) | TSHRCYP3A4MEN1THRBHTT | |
| Ether SCHEMBL351284 | 0.97 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| Ether SCHEMBL11371854 | 0.94 | TSHR (0.55) | TSHRCYP3A4MEN1THRBHTT | |
| Ether SCHEMBL8463434 | 0.93 | TSHR (0.52) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL23356864 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL15023631 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL6139406 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL616138 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| Ether SCHEMBL8587958 | 0.90 | HTT (0.56) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL274644 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115337450-A | 3D printing elastic support with porous fibers and preparation method and application thereof | 四川大学 | 2022-11-15 | — | — | CN | claimed |
| US-11326051-B2 | Method for producing oxymethylene polymer and oxymethylene polymer resin composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-05-10 | — | — | US | claimed |
| CN-103570710-A | Praziquantel preparation process | SHANGHAI DESANO CHEMICAL PHARM | 2014-02-12 | — | — | CN | claimed |
| CN-101386592-A | Method for preparing pitavastatin calcium raw material medicine using asymmetric hydrogenation | UNIV SHANGHAI JIAOTONG (CN) | 2009-03-18 | — | — | CN | claimed |
| US-11621438-B2 | Solid electrolyte interphase (SEI) application on anode of fluoride ion/shuttle batteries | HONDA MOTOR CO., LTD. (JP) | 2023-04-04 | — | — | US | disclosed |
| EP-3613748-B1 | METHOD FOR THE PREPARATION OF TRIALKYL GALLIUM COMPOUNDS | UMICORE AG & CO KG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-20200185776-A1 | SOLID ELECTROLYTE INTERPHASE (SEI) APPLICATION ON ANODE OF FLUORIDE ION/SHUTTLE BATTERIES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-06-11 | — | — | US | disclosed |
| CN-105917512-B | Secondary battery and method for manufacturing secondary battery | 株式会社东芝 | 2020-05-26 | — | — | CN | disclosed |
| US-10648304-B2 | Method of using surface modifying treatment agents to treat subterranean formations | BAKER HUGHES, A GE COMPANY, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| CN-110355497-A | A kind of New Flux and preparation method thereof | 常州亚玛顿股份有限公司 | 2019-10-22 | — | — | CN | disclosed |
| US-10428089-B2 | Method for producing trialkylgallium compounds and the use thereof | UMICORE AG & CO. KG (DE) | 2019-10-01 | — | — | US | disclosed |
| CN-110240822-A | A kind of aqueous polyamide anti-settling agent and preparation method thereof | 珠海华夏奔腾化工有限公司 | 2019-09-17 | — | — | CN | disclosed |
| EP-0598093-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LIMITED (GB) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993024486-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHETASE INHIBITORS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | disclosed |
| WO-1991004993-A1 | FUNCTIONALIZATION OF POLYMERIC ORGANOLITHIUM COMPOUNDS BY CARBONATION | EXXON CHEMICAL PATENTS INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4829072-A | BACTERICIDES, FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1989-05-09 | — | — | US | disclosed |
| CN-87100686-A | 3-alkoxyl group-2-aminopropylamines as cardiovascular agents | — | 1987-10-14 | — | — | CN | disclosed |
| US-4387190-A | Autoxidizable compositions containing low molecular weight polymers of dicyclopentenyl methacrylate or dicyclopentenyloxyalkyl methacrylate | ROHM & HAAS COMPANY (US) | 1983-06-07 | — | — | US | disclosed |
| US-4235815-A | N-fluoromethyl-carbamic acid fluorides and their manufacture | BASF AKTIENGESELLSCHAFT (DE) | 1980-11-25 | — | — | US | disclosed |
| US-4219499-A | INTERMEDIATES FOR HERBICIDES, DYES AND ANTICARCINOGENS | BASF AKTIENGESELLSCHAFT (DE) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428089-B2 | Method for producing trialkylgallium compounds and the use thereof | MGAM, GALC, AGL | TSHR 2184/4885CYP3A4 1961/4885MEN1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.